Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Alto Neuroscience Inc ANRO

Healthcare Biotechnology
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b... see more

Current News (NYSE:ANRO)

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)

GlobeNewswire December 1, 2025

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Business Wire November 12, 2025

NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days

PR Newswire November 11, 2025

Alto Neuroscience to Participate in Upcoming Investor Conferences

Business Wire October 28, 2025

Alto Neuroscience Announces $50 Million Private Placement Financing

Business Wire October 20, 2025

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Business Wire October 20, 2025

Lifshitz Law PLLC Announces Investigations of Centene Corporation (NYSE: CNC), Capricor Therapeutics, Inc. (NASDAQ: CAPR), Neogen Corporation (NASDAQ: NEOG), and Alto Neuroscience, Inc. (NYSE: ANRO)

ACCESS Newswire October 16, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

GlobeNewswire October 8, 2025

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire October 7, 2025
View More News ››

Opinion & Analysis (NYSE:ANRO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:ANRO)

Buy buddy buy.

Otherwise it will be FOMO time for you fellas out there today anyway
coolfooldumbguy - October 3, 2025

It's TIME!

Bought the stock on the hills of the trial news.........this one could run back to 5$ pretty easy!
OxideHL24 - October 25, 2024
View more Bullboard ››

Sky Gold Corp.

Sky Gold Corp.

Sky Gold Corp., a junior mineral exploration company, engages in the exploration and development of mineral properties in ...
View More »